{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:02:58Z","timestamp":1789473778287,"version":"build-2803163510"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Melbourne Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40257-026-01060-z","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:07:43Z","timestamp":1785258463000},"page":"925-943","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Oral Janus Kinase Inhibitors in Adults and Adolescents with Alopecia Areata: A Systematic Review and Meta-Analysis of Randomised Controlled Trials"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-7391","authenticated-orcid":false,"given":"Samuel","family":"Morriss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan Hui","family":"Foo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Rodrigues Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella","family":"Kushnir-Grinbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"FitzGerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalem","family":"Leemaqz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bevin","family":"Bhoyrul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"1060_CR1","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"CH Pratt","year":"2017","unstructured":"Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011.","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"1060_CR2","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1046\/j.1365-4362.2002.01357.x","volume":"41","author":"E Tan","year":"2002","unstructured":"Tan E, Tay YK, Goh CL, Chin GY. The pattern and profile of alopecia areata in Singapore: a study of 219 Asians. Int J Dermatol. 2002;41(11):748\u201353.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1060_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","volume":"85","author":"A Toussi","year":"2021","unstructured":"Toussi A, Barton VR, Le ST, Agbai ON, Kiuru M. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review. J Am Acad Dermatol. 2021;85(1):162\u201375.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1060_CR4","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jaad.2019.05.086","volume":"88","author":"JP Okhovat","year":"2023","unstructured":"Okhovat JP, Marks DH, Manatis-Lornell A, Hagigeorges D, Locascio JJ, Senna MM. Association between alopecia areata, anxiety, and depression: a systematic review and meta-analysis. J Am Acad Dermatol. 2023;88(5):1040\u201350.","journal-title":"J Am Acad Dermatol"},{"issue":"15","key":"1060_CR5","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89776","volume":"1","author":"M Kennedy Crispin","year":"2016","unstructured":"Kennedy Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776.","journal-title":"JCI Insight"},{"issue":"15","key":"1060_CR6","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89790","volume":"1","author":"J Mackay-Wiggan","year":"2016","unstructured":"Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15):e89790.","journal-title":"JCI Insight"},{"issue":"7","key":"1060_CR7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/ajd.14556","volume":"66","author":"M Thomas","year":"2025","unstructured":"Thomas M, Hankins M, Darchini-Maragheh E, Bokhari L, Eisman S, Yip L, et al. Criteria for commencing and continuing subsidised Janus kinase inhibitor therapy in Australian alopecia areata patients: results from an Australian expert consensus exercise. Australas J Dermatol. 2025;66(7):404\u201312.","journal-title":"Australas J Dermatol"},{"key":"1060_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1577115","volume":"16","author":"Y Sun","year":"2025","unstructured":"Sun Y, Li Q, Zhang Y, Liu Y. Janus kinase inhibitors for alopecia areata: a review of clinical data. Front Immunol. 2025;16:1577115.","journal-title":"Front Immunol"},{"issue":"3","key":"1060_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","volume":"24","author":"O Kwon","year":"2023","unstructured":"Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443\u201351.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1060_CR10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/bjd\/ljac059","volume":"188","author":"B King","year":"2023","unstructured":"King B, Mostaghimi A, Shimomura Y, Zlotogorski A, Choi GS, Blume-Peytavi U, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2023;188(2):218\u201327.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1060_CR11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/jdv.19665","volume":"38","author":"M Senna","year":"2024","unstructured":"Senna M, Mostaghimi A, Ohyama M, Sinclair R, Dutronc Y, Wu WS, et al. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. J Eur Acad Dermatol Venereol. 2024;38(3):583\u201393.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1060_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17829","author":"M Wada-Irimada","year":"2025","unstructured":"Wada-Irimada M, Takahashi T, Sekine M, Okazaki T, Takahashi T, Chiba T, et al. Long-term real-world outcomes of baricitinib in severe alopecia areata: a 104-week retrospective analysis from a single institute. J Dermatol. 2025. https:\/\/doi.org\/10.1111\/1346-8138.17829. (Epub ahead of print).","journal-title":"J Dermatol"},{"issue":"10","key":"1060_CR13","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s13555-025-01517-9","volume":"15","author":"K Sanchez","year":"2025","unstructured":"Sanchez K, Englander H, Salloum L, Gregoire S, Biba U, Ershadi S, et al. Evaluating current and emergent JAK inhibitors for alopecia areata: a narrative review. Dermatol Ther (Heidelb). 2025;15(10):2749\u201364.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"2","key":"1060_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/bjd\/ljae365","volume":"192","author":"M Piliang","year":"2025","unstructured":"Piliang M, Soung J, King B, Shapiro J, Rudnicka L, Farrant P, et al. Efficacy and safety of the oral Janus kinase 3\/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb\/III and long-term phase III clinical studies in alopecia areata. Br J Dermatol. 2025;192(2):215\u201327.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1060_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021;85(2):379\u201387.","journal-title":"J Am Acad Dermatol"},{"issue":"10387","key":"1060_CR16","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023;401(10387):1518\u201329.","journal-title":"Lancet"},{"issue":"5","key":"1060_CR17","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","volume":"91","author":"B King","year":"2024","unstructured":"King B, Senna MM, Mesinkovska NA, Lynde C, Zirwas M, Maari C, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024;91(5):880\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"1060_CR18","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399.","journal-title":"N Engl J Med"},{"issue":"5","key":"1060_CR19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.063","volume":"89","author":"C Zhou","year":"2023","unstructured":"Zhou C, Yang X, Yang B, Yan G, Dong X, Ding Y, et al. A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata. J Am Acad Dermatol. 2023;89(5):911\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1060_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaad.2025.09.044","volume":"94","author":"C Zhou","year":"2026","unstructured":"Zhou C, Yang C, Fan W, Wu J, Yang D, Jin H, et al. Ivarmacitinib for the treatment of adults with severe alopecia areata: results from a phase 3 trial. J Am Acad Dermatol. 2026;94(1):161\u201371.","journal-title":"J Am Acad Dermatol"},{"key":"1060_CR21","unstructured":"National Library of Medicine. A study to evaluate the safety and effectiveness of upadacitinib tablets in adult and adolescent participants with severe alopecia areata (Up-AA). 2025. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06012240. (Accessed 15 Jul 2026)."},{"key":"1060_CR22","unstructured":"National Library of Medicine. Efficacy and safety of JAK inhibitors in patients with AA: RWE Study 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06573593. (Accessed 15 Jul 2026)."},{"key":"1060_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1060_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"1060_CR25","unstructured":"Skelly CL, McMahon K, Munakomi S. Adverse Events. In: StatPearls. Treasure Island (FL): StatPearls Publishing LLC; 2026."},{"key":"1060_CR26","unstructured":"National Library of Medicine. Serious Adverse event. Available from: https:\/\/www.ncbi.nlm.nih.gov\/medgen\/276798. (Accessed 15 Jul 2026)."},{"issue":"7","key":"1060_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03203-w","volume":"316","author":"M Paracha","year":"2024","unstructured":"Paracha M, Wasim M, Noor SM, Khan AQ, Sagheer F, Ahmad I. Comparison of efficacy and safety of tofacitinib and azathioprine in patients with alopecia areata and variants: a double-blind, randomized controlled trial. Arch Dermatol Res. 2024;316(7):458.","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"1060_CR28","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.jaad.2025.11.070","volume":"94","author":"A Tsianakas","year":"2026","unstructured":"Tsianakas A, Passeron T, Magnolo N, Blume-Peytavi U, Kelly V, Day I, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1\/2 inhibitor, in adults with alopecia areata: results from the THRIVE-AA2 phase 3, randomized, double-blind, controlled trial. J Am Acad Dermatol. 2026;94(4):1134\u201343. https:\/\/doi.org\/10.1016\/j.jaad.2025.11.070.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1060_CR29","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, Ko J, Forman S, Ohyama M, Mesinkovska N, Yu G, et al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study. J Am Acad Dermatol. 2021;85(4):847\u201353.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1060_CR30","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jaad.2022.03.045","volume":"87","author":"B King","year":"2022","unstructured":"King B, Mesinkovska N, Mirmirani P, Bruce S, Kempers S, Guttman-Yassky E, et al. Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus kinase inhibitor, in moderate-to-severe alopecia areata. J Am Acad Dermatol. 2022;87(2):306\u201313.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1060_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1204","volume":"12","author":"S Anderson","year":"2024","unstructured":"Anderson S, Cavaletti G, Hood LJ, Polydefkis M, Herrmann DN, Rance G, et al. A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata. Pharmacol Res Perspect. 2024;12(4):e1204.","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"1060_CR32","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.jaad.2025.11.070","volume":"94","author":"A Tsianakas","year":"2026","unstructured":"Tsianakas A, Passeron T, Magnolo N, Blume-Peytavi U, Kelly V, Day I, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1\/2 inhibitor, in adults with alopecia areata: results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial. J Am Acad Dermatol. 2026;94(4):1134\u201343.","journal-title":"J Am Acad Dermatol"},{"key":"1060_CR33","unstructured":"King B. Results from THRIVE-AA2: a double blind, placebo controlled phase 3 clinical trial of deuruxolitinib (CTP543), an oral JAK inhibitor, in adult patients with moderate to severe alopecia areata. AAD Annual Meeting 2023. Available from: https:\/\/www.biomedtracker.com\/EventFiles\/Concert%202023-03-18%20CTP-543%20Phase%20III%20Updated%20Results%20AAD%20Slides.pdf. (Accessed 15 Jul 2026)."},{"issue":"1","key":"1060_CR34","doi-asserted-by":"publisher","first-page":"2444494","DOI":"10.1080\/09546634.2024.2444494","volume":"36","author":"CA Vignoli","year":"2025","unstructured":"Vignoli CA, Gargiulo L, Ibba L, Balato A, Barbareschi M, Barruscotti S, et al. Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study. J Dermatolog Treat. 2025;36(1):2444494.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"1060_CR35","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/jdv.70067","volume":"40","author":"BM Piraccini","year":"2026","unstructured":"Piraccini BM, Cedirian S, Pampaloni F, Rapparini L, Quadrelli F, Bruni F, et al. Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results. J Eur Acad Dermatol Venereol. 2026;40(2):224\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"1060_CR36","doi-asserted-by":"publisher","first-page":"e1019","DOI":"10.1111\/jdv.20747","volume":"39","author":"J Naharro-Rodr\u00edguez","year":"2025","unstructured":"Naharro-Rodr\u00edguez J, Berna-Rico E, Hermosa-Gelbard \u00c1, Buend\u00eda-Casta\u00f1o D, Va\u00f1\u00f3-Galv\u00e1n S, Saceda-Corralo D. Real-world efficacy and safety of baricitinib combined with corticosteroids in alopecia areata. J Eur Acad Dermatol Venereol. 2025;39(12):e1019\u201321.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1060_CR37","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/ajd.14325","volume":"65","author":"W Cranwell","year":"2024","unstructured":"Cranwell W, Meah N, Wall D, Bhoyrul B, Laita B, Sinclair RD. Real-world effectiveness and safety of tofacitinib for alopecia areata: a retrospective cohort study of 202 patients. Australas J Dermatol. 2024;65(6):505\u201313.","journal-title":"Australas J Dermatol"},{"issue":"5","key":"1060_CR38","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.jaad.2025.07.008","volume":"93","author":"J Huang","year":"2025","unstructured":"Huang J, Jian J, Li M, Ji R, Tian T, Liang X, et al. Real-world efficacy of ritlecitinib in treating alopecia areata across various anatomical sites: potential rapid response predictors. J Am Acad Dermatol. 2025;93(5):1236\u201342.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1060_CR39","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1093\/ced\/llaf312","volume":"50","author":"L Valtellini","year":"2025","unstructured":"Valtellini L, Avallone G, Murgia G, Perego G, Giunipero di Corteranzo I, Vignoli CA, et al. Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study. Clin Exp Dermatol. 2025;50(11):2297\u2013300.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"1060_CR40","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40257-026-01022-5","volume":"27","author":"M Starace","year":"2026","unstructured":"Starace M, Rapparini L, Pampaloni F, Cedirian S, Quadrelli F, Bruni F, et al. Ritlecitinib for severe alopecia areata: a 24-week, multicentre, real-world study. Am J Clin Dermatol. 2026;27(3):621\u201330.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1060_CR41","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.15489","volume":"33","author":"K Phan","year":"2019","unstructured":"Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33(5):850\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1060_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950450","volume":"13","author":"D Yan","year":"2022","unstructured":"Yan D, Fan H, Chen M, Xia L, Wang S, Dong W, et al. The efficacy and safety of JAK inhibitors for alopecia areata: a systematic review and meta-analysis of prospective studies. Front Pharmacol. 2022;13:950450.","journal-title":"Front Pharmacol"},{"key":"1060_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1195858","volume":"14","author":"MQ Mao","year":"2018","unstructured":"Mao MQ, Ding YX, Jing J, Tang ZW, Miao YJ, Yang XS, et al. The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients. Front Immunol. 2018;14:1195858.","journal-title":"Front Immunol"},{"key":"1060_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1152513","volume":"14","author":"D Wei","year":"2023","unstructured":"Wei D, Chen Y, Shen Y, Xie B, Song X. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis. Front Immunol. 2023;14:1152513.","journal-title":"Front Immunol"},{"issue":"6","key":"1060_CR45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.20351","volume":"6","author":"M Liu","year":"2023","unstructured":"Liu M, Gao Y, Yuan Y, Yang K, Shen C, Wang J, et al. Janus kinase inhibitors for alopecia areata: a systematic review and meta-analysis. JAMA Netw Open. 2023;6(6):e2320351.","journal-title":"JAMA Netw Open"},{"key":"1060_CR46","doi-asserted-by":"publisher","first-page":"adv00855","DOI":"10.2340\/actadv.v103.4536","volume":"103","author":"F Barati Sedeh","year":"2023","unstructured":"Barati Sedeh F, Michaelsd\u00f3ttir TE, Henning MAS, Jemec GBE, Ibler KS. Comparative efficacy and safety of Janus kinase inhibitors used in alopecia areata: a systematic review and meta-analysis. Acta Derm Venereol. 2023;103:adv00855.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1060_CR47","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/jdv.19797","volume":"38","author":"H Husein-ElAhmed","year":"2024","unstructured":"Husein-ElAhmed H, Husein-ElAhmed S. Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: a systematic review and Bayesian network meta-analysis. J Eur Acad Dermatol Venereol. 2024;38(5):835\u201343.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1060_CR48","unstructured":"US Food and Drug Administration. Janus kinase (JAK) inhibitors: drug safety communication. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death. 2021. https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk. (Accessed 15 Jul 2026)."},{"issue":"11","key":"1060_CR49","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1080\/1744666X.2023.2249237","volume":"19","author":"K Tokareva","year":"2023","unstructured":"Tokareva K, Reid P, Yang V, Liew D, Peterson AC, Baraff A, et al. JAK inhibitors and black box warnings: what is the future for JAK inhibitors? Expert Rev Clin Immunol. 2023;19(11):1385\u201397.","journal-title":"Expert Rev Clin Immunol"},{"key":"1060_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1576553","volume":"16","author":"Z Qi","year":"2025","unstructured":"Qi Z, Li Y. Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis. Front Pharmacol. 2025;16:1576553.","journal-title":"Front Pharmacol"},{"key":"1060_CR51","doi-asserted-by":"publisher","first-page":"adv42990","DOI":"10.2340\/actadv.v105.42990","volume":"105","author":"SC Van Helmond","year":"2025","unstructured":"Van Helmond SC, Willaert M, Nguyen VH, Nijsten T, Waalboer-Spuij R, Hijnen D. Real-world effectiveness and safety of Janus kinase inhibitors in alopecia areata: a retrospective cohort study of 72 patients. Acta Derm Venereol. 2025;105:adv42990.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1060_CR52","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.jaad.2025.11.064","volume":"94","author":"M Senna","year":"2026","unstructured":"Senna M, Mostaghimi A, Sinclair R, Ohyama M, Chiasserini C, Yu G, et al. Maintenance of long-term efficacy with continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2. J Am Acad Dermatol. 2026;94(4):1126\u201333.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1060_CR53","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/ijd.13598","volume":"56","author":"A Vandiver","year":"2017","unstructured":"Vandiver A, Girardi N, Alhariri J, Garza LA. Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring. Int J Dermatol. 2017;56(8):833\u20135.","journal-title":"Int J Dermatol"},{"issue":"5","key":"1060_CR54","doi-asserted-by":"publisher","first-page":"621","DOI":"10.25259\/IJDVL_975_19","volume":"87","author":"DA Yu","year":"2021","unstructured":"Yu DA, Kim YE, Kwon O, Park H. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: a systematic review and meta-analysis. Indian J Dermatol Venereol Leprol. 2021;87(5):621\u20137.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"1060_CR55","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jaad.2024.09.025","volume":"92","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Wang F, Li X, Zhao Y, Zhang J, Zhao W, et al. Oral abrocitinib for treatment of refractory alopecia areata: a retrospective study. J Am Acad Dermatol. 2025;92(1):153\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1060_CR56","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.abd.2024.11.004","volume":"100","author":"J Lin","year":"2025","unstructured":"Lin J, Li Z, Shen L, Lin JM, Tao K, Miao Y, et al. Successful treatment of severe diffuse alopecia areata with abrocitinib. An Bras Dermatol. 2025;100(3):580\u20132.","journal-title":"An Bras Dermatol"},{"issue":"3","key":"1060_CR57","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/bjd\/ljac103","volume":"188","author":"N Fagan","year":"2023","unstructured":"Fagan N, Doherty GA, Meah N, Sinclair R, Wall D. Cross-specialty identification of the JAK1 inhibitor trial agent filgotinib as a potential therapy for alopecia areata. Br J Dermatol. 2023;188(3):442\u20133.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1060_CR58","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1111\/ijd.17783","volume":"64","author":"F Alinaghi","year":"2025","unstructured":"Alinaghi F, Thein D, Ammitzb\u00f8ll-Danielsen M, Thomsen SF. A first case of complete resolution of hair loss in a patient with rheumatoid arthritis and concomitant alopecia universalis treated with filgotinib. Int J Dermatol. 2025;64(10):1917\u20139.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1060_CR59","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jaad.2025.04.070","volume":"93","author":"Q Wang","year":"2025","unstructured":"Wang Q, Shen L, Sha Y, Tao K, Lin JM, Zhou L, et al. Upadacitinib for refractory alopecia areata unresponsive to prior systemic therapies: a retrospective study. J Am Acad Dermatol. 2025;93(3):761\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1060_CR60","first-page":"269","volume":"94","author":"F Chambres","year":"2026","unstructured":"Chambres F, T\u00e9tart F, Janela-Lapert R, Aubert H, Raison-Peyron FN, S\u00e9v\u00e9rino-Freire M, et al. Efficacy of upadacitinib in patients with severe alopecia areata, including baricitinib-refractory cases: a case series of 22 patients. J Am Acad Dermatol. 2026;94(1):269\u201371.","journal-title":"J Am Acad Dermatol"},{"key":"1060_CR61","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.2147\/CCID.S549823","volume":"18","author":"Y Gao","year":"2025","unstructured":"Gao Y, Zhu C, Jin H. Upadacitinib therapy in adolescent severe alopecia areata: a case series and narrative review. Clin Cosmet Investig Dermatol. 2025;18:2141\u20138.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1060_CR62","unstructured":"AbbVie. AbbVie announces positive topline results from second phase 3 UP-AA trial evaluating upadacitinib (Rinvoq\u00ae) for alopecia areata. 2025. https:\/\/news.abbvie.com\/2025-08-21-AbbVie-Announces-Positive-Topline-Results-from-Second-Phase-3-UP-AA-Trial-Evaluating-Upadacitinib-RINVOQ-R-for-Alopecia-Areata. (Accessed 15 Jul 2026)."},{"key":"1060_CR63","doi-asserted-by":"publisher","first-page":"2050313x2312131","DOI":"10.1177\/2050313X231213135","volume":"11","author":"S Oliel","year":"2023","unstructured":"Oliel S, Moussa S, Stanciu M, Netchiporouk E. Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: a case report. SAGE Open Med Case Rep. 2023;11:2050313x231213135.","journal-title":"SAGE Open Med Case Rep."},{"issue":"2","key":"1060_CR64","first-page":"234","volume":"23","author":"C Jonas","year":"2025","unstructured":"Jonas C, Sch\u00f6n MP, M\u00f6ssner R. Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy. JDDG J Dtsch Dermatol Ges. 2025;23(2):234\u20135.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"issue":"12","key":"1060_CR65","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1093\/ced\/llaf345","volume":"50","author":"SS Yong","year":"2025","unstructured":"Yong SS, Bhoyrul B. Complete hair regrowth in a patient with severe alopecia areata treated with deucravacitinib. Clin Exp Dermatol. 2025;50(12):2501\u20132.","journal-title":"Clin Exp Dermatol"},{"key":"1060_CR66","unstructured":"National Library of Medicine. A study to evaluate efficacy and safety of deucravacitinib in participants with alopecia areata. 2025. https:\/\/clinicaltrials.gov\/study\/NCT05556265. (Accessed 15 Jul 2026)."},{"key":"1060_CR67","unstructured":"National Library of Medicine. A study of KL130008 in adults with severe alopecia areata. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05496426. (Accessed 15 Jul 2026)."},{"key":"1060_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106257","volume":"176","author":"N Li","year":"2022","unstructured":"Li N, Du S, Wang Y, Zhu X, Shu S, Men Y, et al. Randomized, double-blinded, placebo-controlled phase I study of the pharmacokinetics, pharmacodynamics, and safety of KL130008, a novel oral JAK inhibitor, in healthy subjects. Eur J Pharm Sci. 2022;176:106257.","journal-title":"Eur J Pharm Sci"},{"key":"1060_CR69","unstructured":"National Library of Medicine. Study to evaluate safety and efficacy of SYHX1901 tablets in severe alopecia areata patients. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06562894. (Accessed 15 Jul 2026)."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01060-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01060-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01060-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:05:36Z","timestamp":1789470336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01060-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1060"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01060-z","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No funding was received for the preparation of this article.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Samuel Morriss, Chuan Hui Foo, Emily Lin, Flavia Rodrigues-Dias, Daniella Kushnir-Grinbaum, Holly FitzGerald, Shalem Leemaqz, Sharon Lee and Bevin Bhoyrul have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","label":"Conflicts of Interest\/Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SM, FD, HF, DK and BB conducted the data extraction. SM and BB conducted the study selection. Statistical analysis was performed by CHF and SL. SM and BB drafted the manuscript. BB revised the final manuscript draft. All authors reviewed, edited and approved the final version of the manuscript.","order":8,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}